Loss of chromosome 1p/19q in oligodendrogliomas represents a powerful predictor of good prognosis. Expression of internexin (INA), a neuronal specific intermediate filament protein, has recently been proposed as a surrogate marker for 1p/19q deletion based on the high degree of correlation between both parameters in oligodendrogliomas. The aim of this study was to assess further the diagnostic utility of INA expression in a set of genetically well-characterized oligodendrogliomas. On the basis of a conservative approach for copy number determination, using both comparative genomic hybridization and fluorescent in situ hybridization, INA expression as a surrogate marker for 1p/19q loss had both reduced specificity (80%) and sensitivity (79%) compared with respective values of 86% and 96% reported in the previous report. The histologic interpretation and diagnostic value of INA expression in oligodendrogliomas should therefore be assessed with greater caution when compared with 1p/ 19q DNA copy number analysis. In addition, DNA copy number aberrations of chromosomes 10, 16, and 17 were detected exclusively in 1p/19q codeleted samples, suggesting that other regions of the genome may contribute to the 1p/19q-deleted tumor phenotype in these samples.
INTRODUCTION
Although long considered to derive from oligodendrocytes (1), there is emerging evidence for neuronal differentiation in oligodendrogliomas with ganglioglioma-like foci, reported previously as oligodendrogliomas (2) . Oligodendroglial areas are also a feature of dysembryoplastic neuroepithelial tumors, and in some dysembryoplastic neuroepithelial tumors, the oligodendroglial areas show neuronal features (3) . In addition, microarray gene expression profiling studies of malignant gliomas have consistently identified a proneural subset that is dominated by anaplastic oligodendrogliomas (4, 5) .
Terminal loss of 1p/19q, mediated through an unbalanced translocation (6) , represents a powerful predictor of good prognosis in gliomas (6Y9) and increased chemosensitivity in oligodendrogliomas (10) . The evidence for neuronal differentiation seems greatest in oligodendrogliomas with 1p/19q deletion, where many genes expressed in these tumors are also expressed in normal brain tissue (11) . Among these genes, >-internexin (INA) displays the greatest differential expression when compared with tumors devoid of a neuronal component (12, 13) . INA is a neuron-specific gene that encodes a 66-kd intermediate filament protein that is widely expressed in neurons of the central and peripheral nervous systems in which it is transported by slow axoplasmic transport in association with neurofilament (14) . The INA protein has been demonstrated by immunohistochemistry in oligodendrogliomas, and based on the level of concordance between INA expression and 1p/19q loss, it has been proposed to be a surrogate marker of 1p/19q deletion (13) .
Microarray-based comparative genomic hybridization (aCGH) allows high-resolution screening of DNA copy number alterations across the genome and has been successfully applied for the analysis of formalin-fixed paraffinembedded (FFPE) tissue samples (15Y17). To interrogate the validity of INA-immunopositive staining as a surrogate marker for 1p/19qYdeleted oligodendroglial tumors, we analyzed its staining pattern in a series of tumors characterized at the DNA copy number level by both 1p/19q fluorescent in situ hybridization (FISH) and aCGH. Although the histologic diagnosis of classic oligodendroglioma (as recently defined [18] ) does not present particular difficulty, the histologic recognition of the oligodendroglial component in mixed oligoastrocytoma and in secondary glioblastoma multiforme is challenging. As reported previously (18) , the correlation between 1p19q expression and classic oligodendroglial histologic diagnosis is so close that it is usually possible to predict 1p19q status on the basis of histologic diagnosis alone.
Here, we assessed the correlation of INA expression with 1p19q status in classic oligodendrogliomas and in oligodendrogliomas lacking classic features, that is, monotonous round nuclei, calcification, nodularity, and distinct microvascular pattern.
MATERIALS AND METHODS

Case Material
Formalin-fixed paraffin-embedded tissue blocks of oligodendroglial tumors were retrieved from the neuropathology files at Beaumont Hospital for the years 2007 to 2010. Hematoxylin and eosinYstained sections were reviewed by 2 experienced neuropathologists, and tumors were graded according to the 2007 World Health Organization (WHO) classification system (1). In the event of disagreement in relation to tumor grade or classification, the tumor was rejected from the study. Areas conforming to oligodendroglioma criteria were selected for further analysis (18) . We included low-grade oligoastrocytomas (both components WHO grade 2) and anaplastic oligoastrocytoma (1 component WHO grade 3). In addition, there were 2 anaplastic oligoastrocytomas with necrosis, which some equate with glioblastoma multiforme (19) , albeit with histologic evidence of a tissue component known to be associated with clinically better outcome, and sometimes referred to as ''secondary glioblastoma,'' and 2 tumors that were initially considered to represent extraventricular neurocytomas but, on imaging review and after repeat surgery, were redesignated as WHO grade 2 oligodendrogliomas. All oligodendroglial areas were graded as either WHO grade 2 or WHO grade 3. In the mixed tumors, only the oligodendroglial component was selected for immunohistochemistry. Care was taken to ensure that parallel sections obtained for CGH included only an oligodendroglial 
Immunohistochemistry
Four-micrometer-thick paraffin sections were immunostained with anti-internexin (Novocastra NCL-A-INTER Clone 2E3 Leica Microsystems, Wetzlar, Germany) at a dilution of 1:100. All of the staining steps, including antigen retrieval, were carried out using the automated BONDMAX stainer (Leica Microsystems). Positive internexin staining was established when more than 10% of cells showed cytoplasmic immunopositivity. Potentially confounding immunopositivity in axons and neurons was minimized by careful previous selection of regions of interest that only contained tumor.
Fluorescent In Situ Hybridization
Four-micrometer-thick parallel FFPE sections were dewaxed and permeabilized with 0.2 M HCl. Sections were incubated in the reducing agent sodium thiocyanate for 30 minutes at 80-C and digested with Proteinase K for 30 minutes at 37-C. Using the Statspin Thermobrite System (IRIS International, Chatsworth, CA), sections were denatured for 11 minutes at 80-C and hybridized at 37-C with 2 dual-color DNA FISH probe sets overnight (Vysis Glioma probe set: LSI 1p36/LSI 1q25 and LSI 19q13/LSI 19p13; Abbott Molecular, Vysis, Des Plaines, IL). Sections were washed in posthybridization buffer for 3 minutes at 74-C. Nuclei were counterstained with 4 ¶,6-diamidino-2-phenylindole (DAPI) and enumerated under an Olympus fluorescence microscope BX51 (Olympus Europa GmbH, Hamburg, Germany), with appropriate filters for DAPI, Spectrum Green, and Texas Red. Ratio calculations of 19q/19p13 and 1p36/1q25 were based on the enumeration of dual signals in a minimum of 60 nonoverlapping nuclei. Fluorescent in situ hybridization was performed on the preceding FFPE section from which DNA had been extracted for aCGH analysis.
DNA Extraction
Four-micrometer-thick FFPE sections taken sequentially and in parallel from the tissue block area submitted for 1p19q deletion testing by FISH were dewaxed using 3 washes of 100% xylene. Samples were then washed twice with 95% ethanol and resuspended in phosphate-buffered saline/water/ Qiagen buffer (Qiagen, Hilden, Germany). DNA was extracted using the formalin-fixed tissue protocol of the Qiagen DNeasy Blood and Tissue Kit according to the manufacturer's instructions. Samples were reprecipitated using 95% ethanol, and DNA quantity and quality were assessed using a Nanodrop 2000 (Nano Drop products, Wilmington, DE).
Array CGH
Methods for microarray hybridization and data analysis were as previously reported (20) and outlined in NimbleGen aCGH protocol v5.1, with minor modifications. Briefly, a total of 500 ng of tumor DNA and reference DNA were differentially labeled with Cy3 and Cy5 (TriLink Biotechnologies, San Diego, CA), respectively, using random primer labeling overnight. The cell line GM10851 (Coriell Cell Repositories, Camden, NJ) was used as a reference in all aCGH experiments. The aCGH protocol was modified to exclude the sonication procedure because the tumor DNA was already partially degraded as a result of the FFPE processing. An additional ethanol DNA precipitation step and overnight fluorescent labeling led to a better labeling yield of the extracted DNA. The labeled samples were combined with 38 KL of NimbleGen Hybridization Buffer (Roche NimbleGen, Inc, Madison, WI) and hybridized onto a 4 Â 72,000K array in a MAUI hybridization station (BioMicro Systems, Salt Lake City, UT) at 42-C for 18 hours. Arrays were washed using NimbleGen posthybridization buffers and dried using centrifugation. Arrays were scanned using the GenePix 4000B Scanner (Molecular Devices, Sunnyvale, CA), and image capture was performed using GenePix 6.0. Using NimbleScan Software Version 2.4, fluorescent intensities were extracted, log 2 ratios were calculated, and qspline were normalized (21); aberration breakpoints were identified using the CGH-segMNT algorithm.
Statistical Analysis
Calculation to determine sensitivity, specificity, and positive and negative predictive values was performed using the clinical calculator 1 at http://faculty.vassar.edu/lowry/ clin1.html.
RESULTS
Comparison of FISH and aCGH Analysis on FFPE Oligodendroglioma Samples
For FISH analysis, a ratio of 0.7 or lower was considered to indicate 1 copy loss. Array CGH log 2 ratio thresholds of j0.2 or less for loss and 0.2 or greater for gain were used to identify DNA copy number imbalances. Of the 44 samples analyzed, 34 displayed complete concordance between FISH and aCGH for the identification of concurrent 1p/19q retention or loss. copy number segments detected in these samples using aCGH. Of the remaining 10 samples, there was agreement in 4 for loss of 1p only; 1 agreed for loss of 19q using both techniques. Where material was available, discrepant cases (T13 and T2) were reanalyzed using a different section of the tumor, and the results obtained after the subsequent aCGH agreed with the original FISH analysis. This suggests that tissue heterogeneity may explain discordant results between the methods. No interstitial 1p or 19q deletions were detected in the tumors, and all deletions identified spanned the region detected by the FISH probes.
Correlation of 1p/19q Loss With INA Expression
Tumors displaying 1p/19q loss or retention by both FISH and aCGH were selected for INA staining (Table 1 -105040096) ; however, 1 case that had an INA deletion stained positively (T26), suggesting that the expression of this protein is not always dosage dependent. For grade 2 oligodendrogliomas (classic), the sensitivity and specificity of INA staining increased to 87.5% and 100%, respectively. Most deletions detected on chromosome 19 encompassed the whole q-arm, whereas deletions on 1p ranged from 1 Mb to 30 to 72 Mb (n = 14) and 1 Mb to 100 to 120 Mb (n = 10). However, survival data for these patients were not available to determine any prognostic difference between the 2 different 1p deletion groups.
Other DNA copy number aberrations common to tumor samples were mapped to define the smallest regions of overlap. Table 2 lists the common regions of loss and gain detected in more than 20% of samples and the frequency at which they occurred in 1p/19qYdeleted samples. Interestingly, the most common region of loss in these samples was detected at the terminal end of chromosomes 4p and 6p. In addition, DNA copy number alterations such as loss of regions of chromosomes 16 and 17, as well as a regional gain of chromosome 10, were observed exclusively in 1p/19q codeleted tumors. From the 24 samples identified as 1p/19q deleted, polysomy for 1q and 19p (which has recently been implicated as a prognostic marker [22] ) was detected in only 3 cases (T18, T26, and T43) for polysomy of 1q and 1 sample (T14) for 19p polysomy. We found no evidence of polysomy of both 1q and 19p in any sample. The sample that harbored an EGFR amplification (T6) was also negative for 1p/19q loss; this result is consistent with that of Ducray et al (11) who reported an inverse correlation between both DNA copy number alterations.
DISCUSSION
The aim of this study was to assess the diagnostic utility of INA expression as a surrogate marker for 1p/19q deletion in oligodendroglial tumors. Array CGH analysis resulted in increased variation in the log 2 ratio data compared with analysis of fresh/frozen tumor material, as previously reported (23) . Refinements to the standard aCGH protocol, including an additional precipitation step and extended fluorescent labeling, improved the results. Only samples that were confirmed by FISH were classified as 1p/19q codeleted and further analyzed. On the basis of routine immunohistochemical staining for INA, we determined that most 1p/19qYcodeleted tumors expressed INA, but we detected false positives and false negatives for this surrogate marker at a higher rate than that described by Ducray et al (13) . We found that the association between 1p/19q codeletion and INA had less specificity (80% vs 86%) and sensitivity (79% vs 96%) when compared with the original report (13) . Considering our conservative approach for copy number determination, using 2 independent cytogenetic techniques, the histologic interpretation and diagnostic value of INA expression in oligodendrogliomas should be assessed with caution.
Alternate mechanisms of gene regulation may be additional complicating factors with respect to using INA as a surrogate marker for 1p/19q loss. We identified loss of INA immunohistochemical expression associated with deletion of the INA locus in 2 tumors (T6 and T32), thus leading to a false-negative result in 1 case. Recently, Ching et al (24) reported transcriptional silencing of INA mediated by RE1 silencing transcription factor (REST) binding and recruitment of histone deacetylase 1 and associated cofactors. Interestingly, the REST locus on 4q12 has previously been reported as being gained in gliomas, and amplification of the REST locus was detected in an oligodendroglioma (25) . Although we did not detect amplifications within this locus, one could speculate that, in rare cases, the forced overexpression of a transcriptional silencer through DNA copy number alterations may affect the levels of INA in tumors.
Other common regions of loss and gain were detected exclusively in 1p/19qYdeleted tumors. A regional gain of chromosome 10 (65433021-68902727) (detected in 33% of 1p/19q samples) harbors 3 genes (ANXA2P3, CTNNA3, and LRRTM3). The LRRTM3 gene has previously been characterized as a member of a gene family encoding leucine-rich repeat transmembrane proteins that are differentially expressed in the nervous system (26) and exhibit synaptogenic activity (27) . These common regions of DNA copy number imbalance on chromosomes 10, 16, and 17 may harbor genes that further contribute to the 1p/19q tumor phenotype and warrant further study on a larger set of tumors. 
